KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Other Non-Current Liabilities (2020 - 2025)

TherapeuticsMD (TXMD) has disclosed Other Non-Current Liabilities for 8 consecutive years, with $871000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non-Current Liabilities rose 23.55% year-over-year to $871000.0, compared with a TTM value of $871000.0 through Sep 2025, up 23.55%, and an annual FY2024 reading of $744000.0, up 16.98% over the prior year.
  • Other Non-Current Liabilities was $871000.0 for Q3 2025 at TherapeuticsMD, up from $832000.0 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $2.1 million in Q4 2021 and bottomed at $358000.0 in Q2 2021.
  • Average Other Non-Current Liabilities over 5 years is $873588.2, with a median of $758000.0 recorded in 2021.
  • The sharpest move saw Other Non-Current Liabilities surged 2065.71% in 2021, then crashed 48.25% in 2022.
  • Year by year, Other Non-Current Liabilities stood at $2.1 million in 2021, then plummeted by 48.25% to $1.1 million in 2022, then tumbled by 42.55% to $636000.0 in 2023, then grew by 16.98% to $744000.0 in 2024, then increased by 17.07% to $871000.0 in 2025.
  • Business Quant data shows Other Non-Current Liabilities for TXMD at $871000.0 in Q3 2025, $832000.0 in Q2 2025, and $795000.0 in Q1 2025.